虽然有前途的多发性硬化症药物Tysabri(那他珠单抗)是从市场上撤出在2005年安全的关注,主动提供从地狱回来,从今天公布的获得三项研究的支持。
基于588个网页-相关网页
Porges points out that there is an FDA-mandated safety study of Copaxone in combination with Tysabri.
FORBES: Biogen Idec Hits A Nerve
Even by itself, Tysabri is twice as effective as any of the existing drugs alone.
Patients in the trial took Tysabri for a year and a half, on average.
FORBES: The Tysabri Game Plan
应用推荐
模块上移
模块下移
不移动